WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 2-Jul-2015 (Data received as of 26-June-2015)
Next overall update Mid July 2015
2014 data are provisional
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 22
GDP / capita (US$): 90'7901 Child (under 5 years) mortality rate: 22

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 537  530  524  516  508  436  382  364 
Births
Surviving infants
Pop. less than 5 years 32  31  30  29  29  28  23  21 
Pop. less than 15 years 94  93  92  91  90  83  66  68 
Female 15-49 years 131  130  129  128  127  109  97  91 

Number of reported case

(Click for retrospective incidence data for Luxembourg)
Diphtheria
Japanese encephalitis
Measles 16  63 
Mumps
Pertussis 30  10  46 
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)**
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Luxembourg)
Vaccine year result method % card seen                                                
BCG         
DTP1          99*  99*  99*  99*  99* 
DTP3          99  99  99*  99  99  90 
HepB_BD          97  97  97 
HepB3          94  94  94  95  95 
Hib3          99  99  99  99 
JapEnc         
MCV          99  99  99  96  96  80 
MCV2          86  86  86 
PCV1          97  95  95 
PCV3          95  95  95  86  86 
Pol3          99*  99*  99*  96  96  90 
Rota1          91 
Rota_last          89  89  89 
Rubella1          95  96  96 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Luxembourg)
DTP1 99  99  99  99  99  96 
DTP3 99  99  99  99  99  90 
HepB3 94  94  95  94  77 
HepB_BD
Hib3 98  99  99  98  93 
MCV 95  99  96  96  91  80 
MCV2 82 
PCV3 95  95  86  86 
Pol3 99  99  99  99  98  90 
Rota_last 89  88  88  87 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 2, 3, 13 months; Yes
DTaPHibIPV 4 months; Yes
DTaPIPV 5-6 years; 15-16 years; Yes every 10 years as a booster
HPV 12-18 years; Yes
Influenza >=65 years; Yes and certain chronic diseases
MMRV 12, 15-23 months; Yes
MenC_conj 13 months; Yes
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps = 60 years; Yes
Rotavirus 2, 3 months; Yes
Typhoid travelers
YF travelers

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR   NA  NA  NA  NA  NA  NA 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number   NA  NA  NA  NA  NA  NA 

System performance

Total Nº districts in country number   NA    NA  NA 
Nº districts with DTP3 coverage >=80% number  
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number              
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR   Yes  Yes  Yes  Yes     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.